US20010046996A1 - Use of a compound for preparing a drug - Google Patents

Use of a compound for preparing a drug Download PDF

Info

Publication number
US20010046996A1
US20010046996A1 US09/784,302 US78430201A US2001046996A1 US 20010046996 A1 US20010046996 A1 US 20010046996A1 US 78430201 A US78430201 A US 78430201A US 2001046996 A1 US2001046996 A1 US 2001046996A1
Authority
US
United States
Prior art keywords
hydrogen
group
positions
lower alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/784,302
Other versions
US6333327B2 (en
Inventor
Lennart Moller
Jan Bergman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/784,302 priority Critical patent/US6333327B2/en
Assigned to LUNDBLAD, LEIF J. I. reassignment LUNDBLAD, LEIF J. I. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERGMAN, JAN, MOLLER, LENNART
Publication of US20010046996A1 publication Critical patent/US20010046996A1/en
Application granted granted Critical
Publication of US6333327B2 publication Critical patent/US6333327B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Definitions

  • the present invention relates to the use of a compound of the general formula I
  • MS is a chronic disease with its origin in the central nervous system (CNS) that often leads to severe consequences. MS can be mild with minor symptoms to severe paralysis and loss of vision. The diagnosis is most common between the ages of 20 to 40 and thereafter the disease continues the remaining life span. Sometimes MS develops rapidly, while in other cases the afflicted persons can live for many decades only with some disabilities.
  • CNS central nervous system
  • MS is more frequent at northern latitudes. Depending on region in the western world the prevalence varies with 50-150 cases per 100,000. In the US only, some 250,000-350,000 have the MS diagnosis. Females have a double risk, compared to males, to develop MS.
  • Interferon-beta (trademarks Avonex R and Betaseron R ) can reduce the symptoms among certain groups of patients and is therefore administered to most patients for ethical reasons. The effect is unclear for the population of MS patients and it is a very expensive treatment.
  • Glatiramer acetate (trademark Copaxone R ) can for some patients reduce the frequence of attacks, but the side effects are substantial and there is a problem to distinguish the symptoms of the MS disease and side effects.
  • MS is a rather common disease that appears early in life. In addition it is a life long disease with severe symptoms. The demand for drugs that can protect the MS patients for the severe development of the disease is therefore of high priority.
  • the compound which according to the present invention is to be used for preparing a drug for treatment of MS is a compound of the following general formula I
  • R 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R 1 can be a hydroxyl group;
  • X is a group —(CH 2 ) n —R 2 , wherein R 2 represents a nitrogen containing basic residue such as NH 2 , NHR 4 or NR 5 R 6 , wherein R 4 , R 5 and R 6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R 3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide.
  • R 1 is preferably selected from hydrogen and lower alkyl groups, especially methyl. More preferably R 1 is methyl in positions 2 and 3 and hydrogen in the other positions. Suitable compounds are such compounds wherein R 1 is hydroxy in one of the positions 7-10, especially in position 9.
  • a compound which has proven to be especially effective is the compound of the following formula II
  • FIG. 1 shows the results obtained in an EAE model test.
  • FIG. 2 shows the results obtained in an EAE rat model test with different doses of a compound used according to the present invention.
  • FIG. 3 shows the effect of pre-treatment with a compound used according to the present invention.
  • FIG. 4 shows the effect of after-treatment with a compound used according to the present invention.
  • the EAE (experimental autoimmune encephalomyelitis) model is a generally accepted animal model for the acute MS symptoms ( (1) Ruuls et al, J. Immunology, 1996, 157, 5721-5731; (2) van der Medide et al, J. Neuroimmunology, 1998, 84, 14-23; (3) Smith et al, Nature Medicine,2000, 6, 1, 62-66).
  • the model is based on Lewis rats that day 0 are induced by 20 ⁇ g myeline peptide (MBP 68-86) och 2 mg of Myobacterium tuberculosis. After one week severe CNS symptoms appear that are by double blind examination given a value—a clinical score. The higher value, the more severe effect.
  • the scale is 0-5. After some 14 days there is a peak in symptoms followed by a decline back to the normal situation.
  • the negative control has no treatment except the immunization (day 0) to induce the acute MS response.
  • FIG. 1 the results from the negative control, Interferon-beta and a compound used according to the present invention, 2,3-dimethyl(dimethylaminoethyl)-5H-indolo-(2,3-b)quinoxaline, (B-220) are shown. From the figure it can be seen that Interferon-beta has no reducing effect of the CNS symptoms.
  • the lower curve represents the tested substance used according to the present invention, which substance surprisingly and unexpectedly reduces the CNS symptoms with 2/3.
  • NOEL intravenous, rat; 12.5 mg/kg bw
  • NOEL cutaneous, rabbit; 200 mg/kg bw
  • FIG. 3 pre-treatment with B-220 before the onset of the disease is shown.
  • the highest curve is illustrating the control without any added B-220 while the lower curve is after administration of B-220 of 6 mg/animal.
  • the pre-treatment results in a clear lowered and delayed MS effect.
  • Administration of B-220 was from ⁇ 7 to +7 days in relation to the onset of disease (day 0).
  • a suitable dosage range for humans is 1 to 50 mg/kg body weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of a compound of formula I
Figure US20010046996A1-20011129-C00001
wherein R1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
X is a group —(CH2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide, for preparing a drug for treatment of MS (multiple sclerosis).

Description

  • The present invention relates to the use of a compound of the general formula I [0001]
    Figure US20010046996A1-20011129-C00002
  • for preparing a drug for treatment of MS (multiple sclerosis). [0002]
  • MS is a chronic disease with its origin in the central nervous system (CNS) that often leads to severe consequences. MS can be mild with minor symptoms to severe paralysis and loss of vision. The diagnosis is most common between the ages of 20 to 40 and thereafter the disease continues the remaining life span. Sometimes MS develops rapidly, while in other cases the afflicted persons can live for many decades only with some disabilities. [0003]
  • MS is more frequent at northern latitudes. Depending on region in the western world the prevalence varies with 50-150 cases per 100,000. In the US only, some 250,000-350,000 have the MS diagnosis. Females have a double risk, compared to males, to develop MS. [0004]
  • It is generally accepted that the immune defense of a patient with MS attacks the CNS, while the exact mechanisms are unknown. Due to inflammation of the nerve isolation (myeline) there are dysfunctions and short-circuits of nerve fibers and thereby effects on the muscles controlled by these nerves. [0005]
  • The treatment of MS is focused on the reduction of symptoms. To cure or stop the MS disease is not possible with today's knowledge. Consequently there does not exist any drug to cure or delay onset of the disease. Treatments used are: [0006]
  • #Transplantation of bone marrow and treatment of cytostatics and lifelong administration of immunosupressive drugs. This method could work for some patients but it is very expensive and includes several risks for the patient. Administration of cytostatics is still considered to be controversial in treatment of MS since the effects are unclear and potential side-effects are severe. [0007]
  • #There are two drugs used with the aim to cure or delay the MS disease; Interferon-beta (trademarks Avonex[0008] R and BetaseronR) can reduce the symptoms among certain groups of patients and is therefore administered to most patients for ethical reasons. The effect is unclear for the population of MS patients and it is a very expensive treatment.
  • Glatiramer acetate (trademark Copaxone[0009] R) can for some patients reduce the frequence of attacks, but the side effects are substantial and there is a problem to distinguish the symptoms of the MS disease and side effects.
  • Today there does not exist an effective treatment for MS. The treatment is focused on reducing symptoms. Tests with transplantation and different drug treatments to cure the disease have so far not shown any solutions. It can work for some patients, although there are risks, side effects and very high costs involved. MS is a rather common disease that appears early in life. In addition it is a life long disease with severe symptoms. The demand for drugs that can protect the MS patients for the severe development of the disease is therefore of high priority. [0010]
  • According to the present invention it has surprisingly been found that a substituted indolo-quinoxaline of the following general formula I can be used for preparing a drug for treatment of MS. [0011]
  • The compound which according to the present invention is to be used for preparing a drug for treatment of MS is a compound of the following general formula I [0012]
    Figure US20010046996A1-20011129-C00003
  • wherein R[0013] 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
  • X is a group —(CH[0014] 2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide. R1 is preferably selected from hydrogen and lower alkyl groups, especially methyl. More preferably R1 is methyl in positions 2 and 3 and hydrogen in the other positions. Suitable compounds are such compounds wherein R1 is hydroxy in one of the positions 7-10, especially in position 9.
  • The compounds used according to the present invention and their preparation are described in EP patent 0238459 and U.S. Pat. No. 4,990,510 which are incorporated herein by reference. [0015]
  • A compound which has proven to be especially effective is the compound of the following formula II [0016]
    Figure US20010046996A1-20011129-C00004
  • In the drawings: [0017]
  • FIG. 1 shows the results obtained in an EAE model test. [0018]
  • FIG. 2 shows the results obtained in an EAE rat model test with different doses of a compound used according to the present invention. [0019]
  • FIG. 3 shows the effect of pre-treatment with a compound used according to the present invention. [0020]
  • FIG. 4 shows the effect of after-treatment with a compound used according to the present invention.[0021]
  • The EAE (experimental autoimmune encephalomyelitis) model is a generally accepted animal model for the acute MS symptoms ( (1) Ruuls et al, J. Immunology, 1996, 157, 5721-5731; (2) van der Medide et al, J. Neuroimmunology, 1998, 84, 14-23; (3) Smith et al, Nature Medicine,2000, 6, 1, 62-66). The model is based on Lewis rats that [0022] day 0 are induced by 20 μg myeline peptide (MBP 68-86) och 2 mg of Myobacterium tuberculosis. After one week severe CNS symptoms appear that are by double blind examination given a value—a clinical score. The higher value, the more severe effect. The scale is 0-5. After some 14 days there is a peak in symptoms followed by a decline back to the normal situation.
  • The negative control has no treatment except the immunization (day 0) to induce the acute MS response. In FIG. 1 the results from the negative control, Interferon-beta and a compound used according to the present invention, 2,3-dimethyl(dimethylaminoethyl)-5H-indolo-(2,3-b)quinoxaline, (B-220) are shown. From the figure it can be seen that Interferon-beta has no reducing effect of the CNS symptoms. The lower curve represents the tested substance used according to the present invention, which substance surprisingly and unexpectedly reduces the CNS symptoms with 2/3. [0023]
  • In the test Interferon-beta was administered daily with 3×10[0024] 5 U/animal which is a medium dose (2). The tested substance(B-220), was administered daily with 6 mg/animal, a dose that can be increased since the margin to toxic effects is wide and most likely further reduce the symptoms. It is to be noted that the acute toxicity of the tested substance used according to the present invention is low, which is exemplified with the following:
  • LD[0025] 50, oral, rat; >800 mg/kg bw
  • LD[0026] 50, intravenous, rat; >100 mg/kg bw
  • NOEL, intravenous, rat; 12.5 mg/kg bw [0027]
  • NOEL, cutaneous, rabbit; 200 mg/kg bw [0028]
  • (NOEL=No Observable Effect Level) [0029]
  • The chronic toxicity has been tested up to 270 days on mice and the substance has not induced toxicity, on the contrary the substance has protected the animals for different health effects. [0030]
  • In the well established EAE rat model for multiple sclerosis (MS) a compound used according to the present invention, B-220, was shown to down-regulate the clinical symptoms (clinical score) in a dose dependent manner. The results are shown in FIG. 2. At the highest dose, 12 mg/animal, (lower curve) the onset is delayed approximate 4 days, the recovery starts approximate 3 days earlier and the total effect is dramatically lowered. A majority of the animals do not show any symptoms at all in this group. Symptom grading 1 is thus a very weak and mild effect while grading 3 is a severe paralysis. The intermediate curve illustrates a dose of 6 mg/animal and the onset is delayed approximate 2 days, the recovery starts approximate 2 days earlier and the total effect is substantially lower as compared to the control, highest curve, where no B-220 is added. [0031]
  • In FIG. 3 pre-treatment with B-220 before the onset of the disease is shown. The highest curve is illustrating the control without any added B-220 while the lower curve is after administration of B-220 of 6 mg/animal. As seen from the Figure the pre-treatment results in a clear lowered and delayed MS effect. Administration of B-220 was from −7 to +7 days in relation to the onset of disease (day 0). [0032]
  • In FIG. 4 after-treatment with B-220 starting from [0033] day 7 from the time point when the disease was initiated (day 0) and throughout the experiment is shown wherein the highest curve is a control without any addition of B-220 and the lower curve is representing a dose of 6 mg/animal of B-220. As seen from the Figure the after-treatment with B-220 lowered the MS effect in the rats.
  • The vertical lines in both FIG. 3 and FIG. 4 represent mean±standard deviation. [0034]
  • A suitable dosage range for humans is 1 to 50 mg/kg body weight. [0035]

Claims (18)

What is claimed is:
1. A method for the treatment of multiple sclerosis comprising administering to a patient in need of said treatment an amount effective therefor of a compound of formula I:
Figure US20010046996A1-20011129-C00005
wherein R1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
X is a group —(CH2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms,
or a physiologically acceptable addition product thereof with an acid or halogen adduct.
2. The method according to
claim 1
 wherein said compound is a physiologically acceptable addition product with an adduct of iodine, iodine monochloride or iodine monobromide.
3. The method of
claim 1
, wherein R1 is methyl in positions 2 and 3 and hydrogen in the other positions, or a physiologically acceptable addition product thereof.
4. The method of
claim 3
, wherein R1 in one of the positions 7-10 is hydroxy.
5. The method of
claim 4
, wherein R1 in position 9 is hydroxy.
6. The method of
claim 2
, wherein R1 in one of the positions 7-10 is hydroxy.
7. The method of
claim 6
, wherein R1 in position 9 is hydroxy.
8. The method of
claim 1
, wherein R1 in one of the positions 7-10 is hydroxy.
9. The method of
claim 8
, wherein R1 in position 9 is hydroxy.
10. The method of
claim 1
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
11. The method of
claim 2
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
12. The method of
claim 3
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
13. The method of
claim 4
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
14. The method of
claim 5
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
15. The method of
claim 6
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
16. The method of
claim 7
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
17. The method of
claim 8
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
18. The method of
claim 9
 wherein X is CH2N(CH3)2 and R3 is hydrogen.
US09/784,302 2000-02-18 2001-02-16 Method for the treatment of Multiple Sclerosis Expired - Fee Related US6333327B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/784,302 US6333327B2 (en) 2000-02-18 2001-02-16 Method for the treatment of Multiple Sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18337200P 2000-02-18 2000-02-18
US09/784,302 US6333327B2 (en) 2000-02-18 2001-02-16 Method for the treatment of Multiple Sclerosis

Publications (2)

Publication Number Publication Date
US20010046996A1 true US20010046996A1 (en) 2001-11-29
US6333327B2 US6333327B2 (en) 2001-12-25

Family

ID=26879045

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/784,302 Expired - Fee Related US6333327B2 (en) 2000-02-18 2001-02-16 Method for the treatment of Multiple Sclerosis

Country Status (1)

Country Link
US (1) US6333327B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502676A (en) * 2004-06-17 2008-01-31 オクシーファルマ エイビー Alkyl-substituted indoloquinoxaline compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE516133C2 (en) * 1999-02-25 2001-11-19 Lundblad Leif J I Use of certain substituted indoloquinoxalins for the preparation of an agent for the protection of tissues, organs and cells during transplantation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (en) * 1986-01-21 1986-01-21 Lundblad Leif SUBSTITUTED INDOLOKINOXALINES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502676A (en) * 2004-06-17 2008-01-31 オクシーファルマ エイビー Alkyl-substituted indoloquinoxaline compounds

Also Published As

Publication number Publication date
US6333327B2 (en) 2001-12-25

Similar Documents

Publication Publication Date Title
DE69233643T2 (en) Use of anticytokin-containing pharmaceutical compositions for the therapy of multiple sclerosis
RU2048812C1 (en) Method of treatment of eye inflammatory diseases and agent for treatment of eye inflammatory diseases
DE69837324T2 (en) TREATMENT OF MULTIPLE SCLEROSIS BY USING COPOLYMER-1
US6395747B1 (en) Remedies for multiple sclerosis
CA2231764A1 (en) Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
EP2523668A1 (en) Treatment of multiple sclerosis
KR20120104445A (en) Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
US6333327B2 (en) Method for the treatment of Multiple Sclerosis
EP1261344B1 (en) Use of indoloquinoxalines for the treatment of multiple sklerosis
JP3415643B2 (en) Drugs for muscular dystrophy
RU2341261C2 (en) Compositions containing epothilones, and application thereof for carcinoid syndrome treatment
Bodansky et al. Parathormone dosage and serum calcium and phosphorus in experimental chronic hyperparathyroidism leading to ostitis fibrosa
JP2000501085A (en) Combination of pentoxifylline and type I interferons for treating multiple sclerosis
EP0190851B1 (en) Improved antiinflammatory composition
KR950007101B1 (en) Therapeutic agent for the treatment of peptic ulcer
Kirkeby et al. Pharmacologically induced erection in patients with multiple sclerosis
US6197818B1 (en) Drug for treating diabetic nephrosis
JP2001526217A (en) Novel use of local anesthetics for vascular headache
JP2005518438A (en) Use of biosynthetic estriol diester prodrugs to treat autoimmune diseases
CN1254597A (en) Antiswelling medicine
Herrick et al. Nervous system involvement in association with vasculitis and anticardiolipin antibodies in a patient with systemic sclerosis.
EP0005074A1 (en) A material and composition for reducing blood pressure
US20150258073A1 (en) INDICATION OF ANTHRA[2,1,c][1,2,5]THIADIAZOLE-6,11-DIONE COMPOUND IN ALLEVIATING PAIN
JPH0656661A (en) Anticataract agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: LUNDBLAD, LEIF J. I., SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOLLER, LENNART;BERGMAN, JAN;REEL/FRAME:011890/0198

Effective date: 20010403

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20131225